First, when the ICOS+ Teff to ICOS+ Treg ratio was measured mice receiving CTLA-4 blockade alone had a large tumor burden, thus the shift in ICOS+ Teff to ICOS+ Treg populations may no longer have been apparent. The gene discussed is CTLA4; the disease is neoplasm.